Zheng Xing Xing Ye Ri Bao·2025-11-03 08:47Market Overview - The biopharmaceutical sector experienced a slight decline of 0.0% on November 3, with Olin Bio leading the drop [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Top Performers - Sangfor Biopharma (688336) saw a significant increase of 7.88%, closing at 78.71 with a trading volume of 220,700 shares and a turnover of 1.754 billion yuan [1] - ST Weiming (002581) rose by 4.99%, closing at 8.20 with a trading volume of 82,400 shares [1] - Other notable gainers included C-Muyuan (688765) with a 3.61% increase, closing at 128.01, and Nossland (920047) with a 3.47% increase, closing at 27.41 [1] Underperformers - Olin Bio (688319) led the declines with a drop of 6.26%, closing at 23.52 and a trading volume of 126,900 shares [2] - Aopumai (688293) fell by 4.95%, closing at 58.82, while Hualan Vaccine (301207) decreased by 3.87%, closing at 21.10 [2] - Other significant losers included Changchun High-tech (000661) and Baiyin Suisi (301080), both experiencing declines of 3.60% [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 155 million yuan from institutional investors, while retail investors contributed a net inflow of 227 million yuan [2] - The overall retail investor net outflow was 71.79 million yuan [2] Individual Stock Capital Flow - Rongchang Bio (688331) had a net inflow of 77.01 million yuan from institutional investors, representing 8.95% of its total [3] - Junshi Biosciences (688180) also saw a significant net inflow of 66.44 million yuan, accounting for 14.16% [3] - Olin Bio (688319) experienced a net outflow of 38.14 million yuan from retail investors, which was 14.13% of its total [3]